...
机译:Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan
Novartis,Novartis Pharma KK;
Japan CDD & Reexaminat CDD2,Novartis Pharma KK;
Japan Biostat Pharma,Novartis Pharma KK;
Canakinumab; hyperimmunoglobulinaemia D syndrome; interleukin-1 beta; mevalonate kinase deficiency; tumour necrosis factor receptor-associated periodic syndrome; MEVALONATE KINASE-DEFICIENCY; AUTOINFLAMMATORY DISEASES; OPEN-LABEL; FEVER; EFFICACY; MANAGEMENT; DIAGNOSIS; FEATURES; SERIES; PYRIN;